Severe acute respiratory syndrome coronavirus 2, commonly abbreviated as SARS-CoV-2, is an enveloped, positive-sense, single-stranded RNA virus belonging to the family Coronaviridae, subfamily Orthocoronavirinae, and genus Betacoronavirus.

It is the causative agent of coronavirus disease 2019, also known as COVID-19, and has had a major global impact on public health, healthcare systems, and society.

SARS-CoV-2 enters host cells primarily through interaction between the viral spike glycoprotein and host-cell receptors. The spike protein binds to angiotensin-converting enzyme 2, which is expressed on a range of human cell types, including cells of the respiratory tract. Following receptor binding, the spike protein is activated by host proteases, enabling fusion of the viral envelope with host-cell membranes and release of the viral genome into the cytoplasm. Viral replication then occurs in association with modified intracellular membranes, where replication-transcription complexes synthesise viral RNA.

The SARS-CoV-2 genome is approximately 30 kb in length, making it one of the largest RNA virus genomes. It encodes several non-structural proteins involved in viral replication and immune modulation, as well as structural proteins required for virion formation. The main structural proteins are the spike, envelope, membrane, and nucleocapsid proteins. The spike protein is particularly important because it mediates host-cell entry, is a major target of neutralising antibodies, and has been central to vaccine and therapeutic antibody development.

A key feature of SARS-CoV-2 is its ability to evolve through the accumulation of mutations, particularly in the spike gene. These genetic changes have led to the emergence of multiple variants with altered transmissibility, immune escape potential, and, in some cases, disease characteristics. Variants such as Alpha, Beta, Gamma, Delta, and Omicron have demonstrated the capacity of SARS-CoV-2 to adapt under population-level immune pressure. Continued viral evolution highlights the importance of genomic surveillance, variant characterisation, and ongoing assessment of vaccine and antiviral effectiveness.

SARS-CoV-2 is transmitted primarily through respiratory droplets and aerosols produced when infected individuals breathe, talk, cough, or sneeze. Transmission is most efficient in close-contact settings, poorly ventilated indoor environments, and crowded spaces. Infection can cause a wide range of clinical outcomes, from asymptomatic infection to severe respiratory disease and multi-organ complications. Common symptoms include fever, cough, sore throat, fatigue, headache, muscle aches, and loss or alteration of smell or taste, although symptom profiles may vary between individuals and viral variants.

Severe COVID-19 is more likely to occur in older adults, immunocompromised individuals, and people with underlying medical conditions such as cardiovascular disease, chronic respiratory disease, diabetes, obesity, or kidney disease. In severe cases, SARS-CoV-2 infection can lead to viral pneumonia, acute respiratory distress syndrome, thrombo-inflammatory complications, and death. Some individuals also experience prolonged symptoms following acute infection, commonly referred to as long COVID, which may include fatigue, breathlessness, cognitive difficulties, and other persistent health problems.

Since its emergence in late 2019, SARS-CoV-2 has caused hundreds of millions of confirmed infections worldwide and substantial mortality. Beyond its direct clinical impact, the COVID-19 pandemic has placed major pressure on healthcare systems, disrupted economies, and accelerated research into viral diagnostics, vaccines, antivirals, and immune responses. The continuing circulation of SARS-CoV-2 means that it remains an important focus of respiratory virus research and public health surveillance.

Vaccination has played a central role in reducing severe disease, hospitalisation, and death caused by SARS-CoV-2. Several vaccine platforms have been developed, including mRNA vaccines, viral vector vaccines, protein-based vaccines, and inactivated virus vaccines. Antiviral therapies, including polymerase inhibitors and protease inhibitors, are also available for selected patients, particularly those at higher risk of severe disease. However, viral evolution, immune escape, unequal access to interventions, and the persistence of vulnerable populations continue to create challenges for long-term control.

Overall, SARS-CoV-2 is a highly transmissible and adaptable respiratory virus with major clinical, scientific, and public health importance. Its ability to evolve, spread efficiently, and cause disease across diverse populations makes it a continuing priority for antiviral discovery, vaccine development, variant monitoring, and host-virus interaction studies